- Previous Close
0.1110 - Open
0.0916 - Bid --
- Ask 0.0893 x 1100
- Day's Range
0.0860 - 0.0964 - 52 Week Range
0.0540 - 1.4800 - Volume
18,347,535 - Avg. Volume
34,712,588 - Market Cap (intraday)
2.574M - Beta (5Y Monthly) 2.03
- PE Ratio (TTM)
-- - EPS (TTM)
-3.8000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
www.petrospharma.com21
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PTPI
View MorePerformance Overview: PTPI
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTPI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTPI
View MoreValuation Measures
Market Cap
2.57M
Enterprise Value
5.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.13
Price/Book (mrq)
0.83
Enterprise Value/Revenue
1.47
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-117.52%
Return on Assets (ttm)
-28.49%
Return on Equity (ttm)
-92.93%
Revenue (ttm)
4.02M
Net Income Avi to Common (ttm)
-19.85M
Diluted EPS (ttm)
-3.8000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.89M
Total Debt/Equity (mrq)
235.49%
Levered Free Cash Flow (ttm)
-1.97M